The European Medicines Agency has recommended marketing authorization for a new hybrid formulation of buprenorphine for opioid drug dependence treatment. Buprenorphine Neuraxpharm, a sublingual film, is intended for use in adults and adolescents 15 years and older. It should be part of a comprehensive treatment plan. This new hybrid medicine is similar to Subutex but has differences in strength and form. The drug is a partial opioid agonist/antagonist and should be prescribed by a doctor experienced in addiction treatment. Common side effects include headache, nausea, and abdominal pain. Buprenorphine Neuraxpharm will be available in multiple strengths once marketing authorization is granted.
Source link